



Purpose Procedural safety and high rates of in-stent re-
current stenotic lesions (iSr) remain a concern in the en-
dovascular treatment of intracranial atherosclerotic disease 
(icaD). in the present study technical feasibility, safety 
and efficacy of the paclitaxel eluting balloon-expandable 
coronary stent Coroflex® Please was assessed in the treat-
ment of icaD.
Methods a total of 95 patients (79 male; median age 68 
years) with 106 intracranial atherosclerotic stenotic lesions 
underwent endovascular treatment using Coroflex® Please 
stents (B. Braun, Melsungen, germany). location and de-
gree of target stenoses before and after treatment and at 
follow-up and adverse clinical sequelae of treatment were 
registered. Post-procedural medication included 100 mg 
acetylsalicylic acid (aSa) and 75 mg clopidogrel for 1 
year. angiographic follow-up was scheduled for 6, 12, 26 
and 52 weeks after the treatment.
Results the lesion locations were as follows: internal ca-
rotid artery (ica) petrous (n = 44, 42%), ica cavernous 
(n = 43, 41%), ica paraclinoid (n = 4, 4%), intradural verte-
bral artery (Va; n = 11, 10%) and basilar artery (Ba; n = 4, 
4%). Of the lesions seven could not be treated due to diffi-
cult anatomy and stent stiffness (7% technical failure rate). 
the combined post-interventional neurological morbidity 
and mortality rate, including stroke, intracerebral hemor-
rhage (icH), subarachnoid hemorrhage (SaH) and carotid 
cavernous fistula (CCF) was n = 4 (3.7%) within and n = 1 
(0.9%) at and beyond 30 days, respectively. angiographic 
and clinical follow-up examinations were carried out for 
78 (78%) of the lesions (mean 16.1 months, maximum 48 
months). asymptomatic recurrent stenosis was seen in 3 
out of 78 (3.8%) lesions and there was 1 case of late stent 
thrombosis (0.9%).
Conclusions treatment of icaD using drug-eluting coro-
nary stents is safe and effective but technical failure due 
to stent stiffness remains a problem. application of the 
more flexible, newest generation thin-strut stents, however, 
shows promising results.
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Introduction
intracranial atherosclerotic stenoses are responsible for at 
least 8–10% of ischemic strokes [1]. the warfarin-aspirin 
symptomatic intracranial disease study (WaSiD, [2]) and 
the extracranial-intracranial bypass study [3] demonstrated 
suboptimal results for the medical or unselected surgical 
management of these lesions. early endovascular attempts 
with balloon dilatation alone did not gain widespread 
adoption due to issues of vessel dissection and early elas-
tic recoiling [4–6] but these issues can be overcome by the 
application of stents. the options for stent treatment in intra-
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cranial stenotic lesions include primary stenting by implan-
tation of a balloon-mounted bare metal [7] and drug-eluting 
stents (DeS; [8–12]) designed originally for the coronary 
vasculature or dedicated for neurovascular application 
[13] or secondary implantation of a slightly oversized self-
expanding stent following a moderately undersized balloon 
dilatation [14]. Despite continuously growing experience in 
patient selection, procedural feasibility, safety and the dura-
bility of revascularization, high rates (24–31%) of recurrent 
stenosis still remain the main drawback of intracranial sten-
ting [15, 16]. achieving lower recurrence rates following 
intracranial stenting is therefore of major importance, alt-
hough promising results of effective re-treatment of recur-
rent in-stent stenotic lesions have been shown recently by 
dilatation using a drug-eluting balloon [17, 18].
The application of sirolimus or paclitaxel eluting balloon 
mounted coronary stents has already been shown to be a 
feasible, efficient and cost-effective treatment of intracra-
nial stenotic lesions [8–12]. The experience is, however, 
still rather limited with a total of 82 published cases to the 
best of our knowledge, performed in several centers apply-
ing a variety of stents and treatment protocols.
This article presents data on the procedural safety, effi-
cacy and mid-term patency rates from a retrospective series 
of stent treatment of 106 intracranial atherosclerotic stenotic 
lesions, performed in a single institution under a standard-
ized periprocedural and postprocedural protocol and patient 
management, using the same type of drug-eluting stent.
Materials and Methods
Patient Selection
the present series comprised 95 consecutive patients who 
underwent elective endovascular treatment of 106 signifi-
cant (≥ 50%) intracranial atherosclerotic arterial stenoses 
in the period from March 2007 to august 2011 in a single 
institution by or under the supervision of the senior author, 
according to identical principles of the entire procedural 
management.
Endovascular treatment using the Coroflex® Please (B. 
Braun, Melsungen, germany) stent was offered to patients 
with an intracranial stenotic lesion, if the lumen loss at the 
stenotic vessel segment was ≥ 50% and this stenosis was 
either symptomatic, progressive or accompanied by other 
stenoses. Previous failure of medical treatment was not con-
sidered a compulsory criterion.
Stenotic lesions located on the intradural internal caro-
tid artery (ica), the intradural vertebral artery (Va) and the 
trunk of the basilar artery (Ba) were included in the study.
Patients were selected for the treatment of stenosis with a 
DeS on the basis of anatomical criteria. arguments in favor 
for the use of a DES were straight proximal vessels without 
excessive atherosclerotic tortuosity, no major caliber diffe-
rences of the target vessel proximal and distal to the stenotic 
segment and a distal vasculature allowing for a sufficiently 
distant insertion of the microguidewire. in addition to formal 
criteria, the anticipated ease or difficulty of the access to a 
given intracranial stenosis with a relatively rigid stent was also 
considered. The extradural or intradural location of the target 
stenosis per se was of no relevance for this decision-making.
All patients were explicitly advised about the off-label 
intracranial use of the drug-eluting coronary stent. (com-
ment: in german jurisdiction, off-label use of medical 
devices is exempt from prosecution, if the patient has a 
serious, e.g. potentially life-threatening disorder, there is no 
reasonable or only a less favorable therapeutic alternative, 
available scientific data justify the expectation that with this 
device a better if not successful outcome could be achieved 
and the patient or legal representative is informed about the 
off-label character as well as about the procedural risks and 
potential treatment alternatives.)
treatment was considered indicated if the target stenosis 
was symptomatic or progressive during follow-up or if the 
affected vessel had no sufficient collaterals or if a steno-
sis of the contralateral vessel has been symptomatic. these 
circumstances are considered to carry an increased risk of 
subsequent cerebral ischemia.
Procedures
the periprocedural management included a neurological 
examination by an independent neurologist prior to and after 
the endovascular treatment, brain magnetic resonance ima-
ging/magnetic resonance angiography (Mri/Mra) and the 
administration of dual medical platelet anti-aggregation the-
rapy. a loading dose of 500 mg acetylsalicylic acid (aSa) 
and 600 mg clopidogrel was given at least 1 day prior to 
treatment followed by 100 mg aSa and 75 mg clopidogrel 
daily for at least 1 year and 100 mg aSa daily thereafter. all 
endovascular procedures were carried out with the patient 
under general anesthesia via a 6 F or 8 F guiding catheter. 
During the procedure, standard medication included 5000 U 
heparin i.v., 500 mg aSa i.v. and 2 mg glycerine trinitrate 
intra-arterially (i.a.) for prevention of mechanically induced 
vasospasm. the target stenosis was visualized without other 
over-projecting vessels and with the least possible foreshor-
tening. the normal vessel diameter adjacent to the stenosis 
and the diameter and length of the stenosis were determined 
using the calibrated measurement program of the Axiom 
artis digital subtraction angiography (DSa) system (Sie-
mens, Erlangen, Germany). Under a single road map the ves-
sel distal to the stenosis was catheterized with a Silverspeed 
(ev3, Irvine, CA, USA) or Traxcess14 (Terumo, Somerset, 
NJ, USA) microguidewire. The diameter of the Coroflex® 
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Please stent was selected to reach about 80% of the diameter 
of the normal vessel. the stents were implanted at nomi-
nal pressure (10 atm) with a manometer. After deflation and 
withdrawal of the balloon catheter a final DSA run was car-
ried out to confirm the result and to exclude complications. 
During the first days after the procedure all possible efforts 
were undertaken to maintain the systolic blood pressure at 
≤ 130 mmHg. Prior to discharge all patients underwent Mri 
as well as a clinical examination. Angiographic follow-up 
was scheduled for 6 and 12 weeks, 6 and 12 months and 
yearly thereafter. the follow-up angiography included DSa 
runs with projections and magnifications equivalent to those 
used for the original treatment. On these occasions patients 
were clinically examined and interviewed specifically for 
intermittent ischemic events.
Results
a total of 95 patients (median age 68 years, age range 44–
84 years, male-to-female ratio 79/16) with 106 intracranial 
atherosclerotic lesions were treated. the lesions were loca-
ted as follows: ica petrous (n = 44, 42%), ica cavernous 
(n = 43, 41%), ica paraclinoid (n = 4, 4%), intradural Va 
(n = 11, 10%) and Ba (n = 4, 4%). the distribution of the 
lesions within the intradural and extradural segments was 
19 (18%) and 87 (82%), respectively.
Of the 106 intracranial lesions 14 (13%) were asympto-
matic, 65 (61%) were symptomatic with transient ischemic 
attacks (tia), stroke or silent infarcts in the area of the affec-
ted vessel and 27 (25%) lesions were treated in the setting 
of multivessel disease. Multivessel disease was defined as 
stenotic lesion of the intracranial ica or Va with occlusion, 
hypoplasia or high-grade stenosis of the corresponding con-
tralateral vessel or segments of the circle of Willis, e.g. mis-
sing a1 segment of the contralateral anterior cerebral artery 
(aca) or missing/hypoplastic P1 segment of the ipsilateral 
posterior cerebral artery (Pca).
the severity of the stenosis was 50–69% in 80 (75%) 
and 70–95% in 26 (25%) of the lesions. the average degree 
of target stenoses was determined as 64.9 ± 1% before and 
16.4 ± 1% after the treatment. a summary of lesion charac-
teristics is given in table 1.
In seven lesions (7%) the Coroflex® Please stent could 
not be advanced into the stenotic segment due to an extremely 
elongated supra-aortic vascular anatomy, an elongated and 
calcified carotid siphon or due to the stiffness of the shaft tip 
or the stent itself. the treatment of these lesions was com-
pleted using either a more flexible bare metal coronary stent 
(Coroflex® Blue Ultra, B. Braun, Melsungen, Germany) or by 
undersized balloon dilatation followed by the implantation 
of a self-expanding nitinol stent (Enterprise, Codman, New 
Brunswick, NJ, USA).
Technical success, defined as less than 50% residual ste-
nosis at the end of the procedure, was achieved in all of the 
cases where the Coroflex® Please stent could be implanted 
(n = 99, 100%; Fig. 1).
Of the procedures where the Coroflex® Please stent could 
be implanted, 94 (94.9%) were completed without any 
complication. A direct carotido-cavernous sinus fistula was 
encountered during the treatment of three stenotic lesions 
(2.8%) of the cavernous ica (two of these lesions were 
symptomatic with tias) as major complication, requiring 
further endovascular treatment. no permanent neurological 
deficit resulted from these dissections. The fourth adverse 
event was a large hemodynamic infarction of the contrala-
teral hemisphere following the treatment of a high-grade 
stenotic lesion of the right cavernous ica and chronic 
occlusion of the left ICA. Due to extreme tortuosity of the 
supra-aortic vessels, direct access was established by direct 
puncture of the cervical right cca. there were no signs of 
complication during the interventional procedure itself. at 
the end of the procedure the patient was transferred to the 
operating room (Or) and the introducer sheet was removed 
surgically. Following extubation the patient developed high 
grade hemiparesis on the right side [modified Rankin Scale 
(mRS) grade 4] with territorial infarcts without significant 
improvement during the 4-month follow-up period, resul-
ting in a procedure related neurological morbidity beyond 
30 days of 0.9%. there was one case (0.9%) of asympto-
matic dissection of the stented segment without any clinical 
relevance. Vasospasm requiring treatment was not encoun-
tered. thus the combined procedure-related neurological 
morbidity and mortality rate, including stroke, intracerebral 
hemorrhage (icH), subarachnoid hemorrhage (SaH) and 
carotid cavernous fistula (CCF) was 4/106 (3.8%) within 30 
days and 1/106 (0.9%) at 30 days and beyond, respectively.
Angiographic and clinical follow-up examinations were 
obtained in 78 (78%) of the lesions. the average follow-up 
period was 16.1 months and the longest follow-up period 
was 48 months.
Recurrent stenosis, defined as an in-stent stenotic lesion 
of more than 50% lumen diameter reduction on the follow-
Table 1 lesion distribution and characteristics




n % n %
ica petrous 29/15 66/34 8/23/13 18/52/30
ica cavernous 36/7 84/16 5/26/12 12/60/28
ica paraclinoid 4/0 100/0 1/2/1 25/50/25
Va/V4 8/3 73/27 0/10/1 0/91/9
Ba 3/1 75/25 0/4/0 0/100/0
total 80/26 75/25 14/65/27 13/61/26
BA basilar artery, ICA internal carotid artery, VA vertebral artery
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up DSa series, was seen in 3 out of 78 (3.8%) lesions after 
190, 224 and 233 days, respectively. all of these recurrent 
lesions were located in the intracranial ica and were asym-
ptomatic (Fig. 2). One case of late stent thrombosis (0.9%) 
occurred 3 months after the DeS implantation in the caver-
nous segment of the left ica in a 60-year-old male pati-
ent. The first DSA follow-up examination in this patient, 6 
weeks after the stent implantation showed full patency of 
the stented segment without any sign of a recurrent lesion. 
the patient suffered from concomitant cardiac arrest with a 
poor clinical outcome.
Stent migration was not observed.
Discussion
atherosclerotic stenotic lesions of the intracranial arteries 
account for 8–10% of ischemic strokes [19]. The efficacy of 
medical and surgical treatment options for intracranial athe-
rosclerotic disease (icaD) is suboptimal: the WaSiD study 
showed that in patients on best medical care, symptomatic 
intracranial disease carried at least a 9–12% annual risk of 
major stroke or death [2], whereas the extracranial-intra-
cranial bypass study demonstrated more frequent and ear-
lier occurrence of both nonfatal and fatal stroke following 
the creation of an extracranial-intracranial (EC-IC) bypass, 
despite the impressive postoperative bypass patency rate of 
96% [3]. the above mentioned issues sparked the interest in 
the endovascular treatment options of ICAD. The experience 
with balloon angioplasty alone without stent implantation is 
limited and results are rather unconvincing with weaknesses, 
such as elastic recoil and dissection [5, 6]. the application 
of balloon-mounted or self-expandable bare metal stents is 
an established treatment option for icaD, although proce-
dural safety and recurrent lesions remain a concern [15]. 
the national institute of neurological Disorders and Stroke 
(ninDS) has recently stopped patient enrollment in the 
Stenting vs. aggressive Medical Management for Preven-
ting recurrent Stroke in intracranial Stenosis (SaMMPriS) 
study, which is the first prospective randomized multicenter 
trial with 50 participating centers in north america, 
evaluating whether intracranial angioplasty combined with 
stenting adds benefit to aggressive medical therapy alone 
for preventing stroke in patients with symptomatic intracra-
nial arterial stenosis [20]. the reason for the premature halt 
was the high periprocedural complication rate with a 14% 
rate of stroke or death in patients treated with angioplasty 
and stenting within the first 30 days, compared with 5.8% of 
patients treated with medical therapy alone, whereas beyond 
30 days, the rates of stroke in the territory of the stenotic 
artery were similar in the 2 groups [21].
High rates of in-stent restenotic (iSr) lesions are also 
problematic: case series of stent treatment for icaD using 
bare metal stents reported hemodynamically significant ISR 
rates from 13.8–37% using bare metal coronary stents [15, 
16] and from 24.7–31% using self-expanding nitinol stents 
[22, 23].
The efficacy of DESs in reducing neointimal hyperplasia, 
late luminal loss and angiographic restenosis over bare metal 
stents in the coronary vasculature has been extensively stu-
died and demonstrated in randomized trials [24]. reports on 
the application of DeSs in the treatment of neurovascular 
Fig. 1 Preprocedural (a), postprocedural (b) and 3-year follow-up digital subtraction angiography (c) of a symptomatic, high-grade stenotic lesion 
of the left internal carotid artery in a 71-year-old female patient, treated by Coroflex® Please DeS deployment.
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stenoses are, however, sparse, with to our knowledge only 
82 reported cases to date. the procedural and iSr results 
with coronary DeS treatment in icaD published so far are 
summarized in table 2.
the results of this study with 3.8% recurrence and 0.9% 
stent occlusion rate at 78% DSa follow-up rate with more 
than 1 year average follow-up period are very promising. 
the very low periprocedural complication rate (0.9% proce-
dure-related morbidity and mortality at and beyond 30 days) 
is also encouraging, especially in the mirror of the recently 
published result of the SaMMPriS trial [27], where the 
poor results in the endovascular arm were mainly attribu-
table to complications of the angioplasty and stenting pro-
cedure. it is a matter of debate whether these complications 
are due to device issues, limited experience and skills of 
the certified operators, poor patient selection, flaws of the 
trial concept or a combination thereof, which is most likely. 
Apart from the specific features of the device, proper patient 
selection is crucial in the endovascular treatment of intra-
cranial stenoses. Patients with high-grade intracranial steno-
ses who have failed several attempts or regimens of medical 
treatment are frequently hemodynamically exhausted and 
therefore prone to postprocedural stroke and reperfusion 
hemorrhage. given the low complication rate of intracranial 
angioplasty and stenting there should be more concern for 
treating patients too late than unnecessarily early.
Dissection of the cavernous ica segment is unrelated to 
the flexibility of the balloon or stent. In some patients caver-
nous ICA stenoses are so calcified and therefore hard and 
the cavernous segment is in the same moment so fragile that 
Fig.  2 Development of a recurrent in-stent stenotic lesion in a 71-
year-old male patient with a symptomatic, high-grade stenosis of the 
petrous segment of the right internal carotid artery. the postprocedural 
digital subtraction angiography image shows an excellent result after 
the deployment of a Coroflex® Please DeS (b), the 7-month follow-up 
examination, however revealed an asymptomatic, high-grade in-stent 
recurrent lesion as a result of intimal hyperplasia (c). Percutaneous 
transluminal angioplasty of the recurrent lesion was performed using 
a drug-eluting (paclitaxel) balloon (Sequent Please, B. Braun; d) with 
very good long-term result (e)
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there is a very thin line between dilatation and dissection of 
the vessel. these dissections occur with every method and 
are a part of the risk profile of these lesions and their treat-
ment. the relative stiffness of coronary DeSs is related to 
access issues but not necessarily to safety concerns.
the main drawback of the application of DeSs in icaD 
seems to be the high rate (7%) of failed attempts, which 
theoretically gets even worse considering the fact that 
patients in whom difficult supra-aortic anatomy or stenosis 
morphology were already known were not even attempted 
to be included in this cohort. the reason behind the high 
rate of procedural failure is the stiffness of the stent sys-
tem of the early generations of coronary DeSs such as the 
Coroflex® Please. Newer generation DESs are far more fle-
xible, mainly as a result of the substantially reduced strut 
thickness. Coroflex® Please features 120 µ thick struts, whe-
reas third generation DeS systems, such as element (Bos-
ton Scientific) or Xience (Abbott, Abbott Park, IL, USA) 
are made of 81 µ thick struts, substantially improving stent 
navigability (unpublished personal observation). the clini-
cal practice was started when the Coroflex® Please was the 
latest stent. It is expected that newer generation DESs will 
combine the low recurrence rate with an improved maneu-
verability, making selected middle cerebral artery (Mca) 
and Ba stenotic lesions also accessible.
recently, the superiority of everolimus-eluting stents over 
paclitaxel-eluting stents with respect to lesion recurrence 
and clinical endpoints has been established in the cardio-
logy literature with in-stent restenosis rates of 2.3% versus 
5.7%, respectively [25, 26]. the application of the newest 
generation, thin-strut DES systems (Element, Xience) with 
everolimus as the eluted drug for the treatment of icaD may 
further improve the already encouraging recurrence rate.
The data presented here are limited in their scientific 
value in several aspects. there was no direct comparison 
with any other treatment method or device, e.g. medical tre-
atment alone or bare metal stent (BMS) procedures. Data 
from primarily clinical series are certainly more prone to 
inconsistencies than those from a strictly regulated and 
externally monitored trial. Patient selection was based on 
the experience and discretion of the senior author, which 
introduces a certain level of individual or at least institu-
tional decision-making. the data were collected in a single 
high volume center. Team experience and well-organized 
infrastructure are factors that contribute largely to the safety 
of a complex procedure such as intracranial angioplasty and 
stenting but are more or less independent from the specific 
device under evaluation. therefore results achieved with a 
certain device or method may or may not be generally appli-
cable to other operators and institutions.
in conclusion, the application of drug-eluting coronary 
stents for intracranial atherosclerotic disease is a safe and 
effective treatment option with low recurrence rates. issues 
of lesion accessibility in difficult anatomical situations 
remain a problem, early experience with the application of 
the more flexible, newest generation thin-strut DES systems, 
however, shows promising results.
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Table 2 review of previous studies on intracranial stenting with drug-eluting stents
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